Why We Fight
CNFWJ is thrilled to announce that its first distribution of funds as an organization went to furthering the administration of clinical trials for what is now the first FDA approved drug that specifically targets NF tumors. Koselugo (selumenitib) – has shown to reduce NF tumor size (20%-60%) in over 70% of pediatric patients in clinical trials. This is monumental in our world. While this is no cure or long-term, stand-alone treatment, it is cause for celebration as we forge a new chapter in the fight against NF.
CNFWJ has raised nearly $3 million on its behalf and on behalf of NF-related entities.
Behind the CNFWJ Board is a broad, multi-state team of volunteers that contribute their time, treasure and talent in the fight against NF. In a short period of time, a community of committed people has developed through CNFWJ – and each year the number and the commitment grows.